Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.64
+0.19 (1.03%)
At close: Nov 4, 2024, 4:00 PM
18.69
+0.05 (0.27%)
After-hours: Nov 4, 2024, 7:29 PM EST
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Teva Pharmaceutical stock have an average target of 19.63, with a low estimate of 11 and a high estimate of 26. The average target predicts an increase of 5.31% from the current stock price of 18.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $22 → $25 | Buy | Maintains | $22 → $25 | +34.12% | Oct 23, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $16 → $18 | Hold | Maintains | $16 → $18 | -3.43% | Oct 21, 2024 |
| UBS | UBS | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +39.48% | Sep 3, 2024 |
| Barclays | Barclays | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +18.03% | Aug 1, 2024 |
| UBS | UBS | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +28.76% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
16.59B
from 15.85B
Increased by 4.70%
Revenue Next Year
17.33B
from 16.59B
Increased by 4.47%
EPS This Year
2.48
from -0.50
EPS Next Year
2.85
from 2.48
Increased by 14.78%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 17.2B | 18.5B | 19.2B |
| Avg | 16.6B | 17.3B | 17.7B |
| Low | 15.9B | 16.0B | 16.2B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 8.6% | 11.6% | 11.0% |
| Avg | 4.7% | 4.5% | 2.0% |
| Low | 0.1% | -3.8% | -6.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 2.60 | 3.26 | 3.16 |
| Avg | 2.48 | 2.85 | 3.00 |
| Low | 2.32 | 2.61 | 2.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 31.1% | 10.9% |
| Avg | - | 14.8% | 5.3% |
| Low | - | 5.0% | -3.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.